Tyrosine kinase inhibitorFDA-approvedSecond-line
Cobimetinib
How it works
Blocks MEK, a protein involved in cell growth and division, which can help slow down cancer growth.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients with BRAF V600E or V600K mutation achieved an objective response, with a median progression-free survival of approximately 12.3 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Combination Therapy for Advanced Ovarian and Endometrial Cancers | Ovarian Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.